Trimetazidine Treatment of Ischemic Heart Disease and Heart Failure Analysis

Objective Myocardial energy metabolism of drugs of trimetazidine and 1,6-diphosphate treatment of ischemic heart disease and heart failure clinical efficacy.Methods Collected 60 cases of ischemic heart disease and heart failure patients,according to the number enrolled randomly divided into observation group and the control group,each group with 30 patients in cardiac,diuretic and vasodilator and other conventional treatment based on,the observation group were given trimetazidine triazine intervention and the control group to be 1,6-diphosphate therapy,two groups of patients compared the efficacy and impact of changes in heart function.Results Observation group was 86.67%,higher than the control group,76.67%,compared the two groups there was statistically significant differenc(P0.05);two groups after treatment than before the improvement in cardiac function LVEDD and LVEF was statistically significant(P0.05),and the observation group of LVEDD and LVEF improvement was better than the control group,there was significant differenc(P0.05).Conclusion Myocardial energy metabolism in drug treatment of ischemic heart disease and heart failure effect is significant and trimetazidine in improving the efficacy and improved cardiac function better than the 1,6-diphosphate,clinical worthy of further study.